BioSpace News Archive

In light of recent media coverage and inquiries, Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively, the “Endo Entities”) have reached a settlement in principle with the County of Cuyahoga, Ohio,

This annual conference will explore personalized medicine, climate change, facial recognition, and more

The leading destination for travel healthcare professionals starting their job search saw 6x revenue growth in the last year

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Teva Pharmaceutical Industries Ltd. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Teva American Depositary Shares between August 4, 2017 and May 10, 2019, inclusive.

Today, the FDA is announcing their next Pediatric Advisory Committee meeting that will cover two areas of interest to the public.

The announcement further emphasizes the innovation in health and science occurring in the Philadelphia market, and will enhance prenatal care for women in the region.

Cook Medical recently released the second generation of the 2.6 Fr CXI Support Catheter with platinum-iridium marker bands.

The Doctors Company announced today the appointment of David L. Feldman, MD, MBA, CPE, FAAPL, FACS, as chief medical officer (CMO) of The Doctors Company Group.

As a part of ClinOne and our CEO’s personal mission, ClinOne will start compensating/reimbursing caregivers of clinical trial participants for their very significant contribution to research, and the incredible amount of support they commit in supporting patients through clinical trials.

Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne.